Journal article icon

Journal article

Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48-week randomized comparison with abacavir/zidovudine/lamivudine in HIV-infected Ugandan adults with low CD4 cell counts.

Abstract:

BACKGROUND: Triple nucleoside reverse transcriptase inhibitor regimens have advantages as first-line antiretroviral therapy (ART), avoiding hepatotoxicity and interactions with anti-tuberculosis therapy, and sparing two drug classes for second-line ART. Concerns exist about virological potency; efficacy has not been assessed in Africa. METHODS: A safety trial comparing nevirapine with abacavir was conducted in two Ugandan Development of Antiretroviral Therapy in Africa (DART) centres: 600 sym...

Expand abstract
Publication status:
Published

Actions


Access Document


Authors


Munderi, P More by this author
More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, Clinical Medicine, Experimental Medicine Division,
Babiker, AG More by this author
Expand authors...
Journal:
HIV medicine
Volume:
11
Issue:
5
Pages:
334-344
Publication date:
2010-05-05
DOI:
EISSN:
1468-1293
ISSN:
1464-2662
URN:
uuid:4440571a-caf8-45d5-8279-4ce7ca7386b8
Source identifiers:
422906
Local pid:
pubs:422906

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP